<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Eur J Rheumatol</journal-id>
<journal-id journal-id-type="iso-abbrev">Eur J Rheumatol</journal-id>
<journal-title-group>
<journal-title>European Journal of Rheumatology</journal-title>
</journal-title-group>
<issn pub-type="ppub">2147-9720</issn>
<issn pub-type="epub">2148-4279</issn>
<publisher>
<publisher-name>Medical Research and Education Association</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31804173</article-id>
<article-id pub-id-type="pmc">7004270</article-id>
<article-id pub-id-type="doi">10.5152/eurjrheum.2019.19160</article-id>
<article-id pub-id-type="publisher-id">ejr-7-suppl1-s3</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pediatric antiphospholipid syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Madison</surname>
<given-names>Jacqueline A.</given-names>
</name>
<xref ref-type="aff" rid="af1-ejr-7-suppl1-s3">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zuo</surname>
<given-names>Yu</given-names>
</name>
<xref ref-type="aff" rid="af2-ejr-7-suppl1-s3">2</xref>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6721-7755</contrib-id>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Knight</surname>
<given-names>Jason S.</given-names>
</name>
<xref ref-type="aff" rid="af2-ejr-7-suppl1-s3">2</xref>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0995-9771</contrib-id>
</contrib>
</contrib-group>
<aff id="af1-ejr-7-suppl1-s3">
<label>1</label>Division of Pediatric Rheumatology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA</aff>
<aff id="af2-ejr-7-suppl1-s3">
<label>2</label>Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA</aff>
<author-notes>
<corresp id="c1-ejr-7-suppl1-s3">Address for Correspondence: Jason S. Knight; Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA, E-mail: <email>jsknight@umich.edu</email></corresp>
<fn fn-type="COI-statement" id="fn3-ejr-7-suppl1-s3">
<p><bold>Conflict of Interest:</bold> The authors have no conflict of interest to declare.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>03</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>7</volume>
<issue>Suppl 1</issue>
<fpage>S3</fpage>
<lpage>S12</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>8</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Â© Copyright by 2020 Medical Research and Education Association</copyright-statement>
<copyright-year>2020</copyright-year>
<license>
<license-p>Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
</license>
</permissions>
<abstract>
<p>Despite its potential to cause significant morbidity in children, pediatric antiphospholipid syndrome (APS) is an understudied condition. In this review, we will cover what is known about pediatric APS epidemiology and how the clinician might approach the diagnosis of pediatric APS. We will highlight similarities and differences with the adult disease, both for primary APS and in the context of lupus. Clinical manifestations beyond thrombosis, especially neurologic and hematologic in nature, will be discussed. We will also consider what unique implications antiphospholipid antibody-positivity may have for children with lupus and for neonates born to mothers with APS. The approach to treatment will be covered, including the unique impact of APS medications on children as compared with adults. Finally, the importance of future mechanistic research is emphasized as physicians endeavor to provide the personalized care that children with APS clearly deserve.</p>
</abstract>
<kwd-group>
<kwd>Antiphospholipid syndrome</kwd>
<kwd>antiphospholipid antibodies</kwd>
<kwd>catastrophic antiphospholipid syndrome</kwd>
<kwd>pediatric</kwd>
<kwd>neonatal</kwd>
<kwd>lupus</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>